USA-based Kailera Therapeutics today announced its launch as a clinical-stage biopharmaceutical company focused on advancing a broad pipeline of next-generation therapies for the treatment of obesity and related conditions. 1 October 2024
Market capitalization of Indian drug makers has taken a hit as the US FDA rains warnings against manufacturing practices, The Pharma letter’s Anjali Shukla tracks the dent. 6 January 2016
Shares in Valeant Pharmaceuticals dropped over 10% on December 28 after the company said chief executive Michael Pearson is taking a medical leave with immediate effect. 4 January 2016
Returns on pharmaceutical research and development are too low for the industry to sustain future pipeline investment, according to a report by the Deloitte Centre for Health Solutions. 14 December 2015
Chinese pharma company Huya Bioscience International said it has opened its first corporate office in Korea, in line with its strategy to accelerate drug development by aiding local firms initiate clinical trials and gain approval for new compounds. 3 December 2015
German pharma giant Merck is considering selling its allergy business Allergopharma in a bid to reduce debts of more than 10 billion euros, according to reports. 30 November 2015
UK pharma major GlaxoSmithKline has cut 40% of its workforce in China as part of the measures to revamp its operations following the infamous bribery scandal. 30 November 2015
Michael Pearson, chief executive of Valeant Pharmaceuticals, warned that the company’s decision to cut ties with its pharmacy partner Philidor would have a negative impact on its dermatology business. 11 November 2015
ValiRx on Thursday said it has set up its US operations in Cambridge, Boston, Massachusetts and has also appointed industry specific advisors in the US. 5 November 2015
Better-than-expected revenues from cancer therapy Opdivo (nivolumab) were a major driver behind Bristol-Myers Squibb beating third quarter profit estimates. 27 October 2015
Reassurance on the future of the UK’s Patent Box Scheme is positive news for UK companies, according to leading intellectual property firm, Withers & Rogers. 26 October 2015
Danish biotech company Genmab said it is set to receive $3 million in milestone payment from Janssen Biotech, a unit of US health care giant Johnson & Johnson, following a pre-clinical advancement for its DuoBody technology platform. 26 October 2015
India’s Piramal Enterprises said the injectables-market review from its pharma solutions unit indicates the near-term growth prospects are highest across generics, small molecule injectables, and in contract services. 14 October 2015
Zealand Pharma on Friday said German drugmaker Boehringer Ingelheim will pay 3 million euros ($3.4 million) in milestones to the company following the selection of a new peptide therapeutic for advanced preclinical development. 9 October 2015
CSL Limited on Friday said it has closed a new 400 million Swiss Franc ($415.8 million) and $100 million via a private placement in the USA. 9 October 2015
Concert Pharmaceuticals on Thursday said it has received $8 million in milestone payments from US biotech company Celgene Corp following the completion of early stage trial of the drug candidate to treat for inflammatory diseases and cancer. 8 October 2015
Paris-based asset manager Kurma Partners has raised 140 million euros ($154 million), successfully completing the first closing of Biofund IV 4 October 2024
Caliway Biopharmaceuticals has successfully completed its initial public offering, raising NT$6.4 billion ($206 million), the largest IPO in Taiwan's biotech industry to date. 3 October 2024
Shares of UK drug developer Hemogenyx Pharmaceuticals rose as much as 9% and closed up 5.9% at 1.70 pence yesterday on the news of a further investment from Prevail Partners. 3 October 2024
UK-based biotech Resolution Therapeutics has announced the completion of a £63.5 million ($76.8 million) series B financing round led by Syncona. 3 October 2024
UK-based biotech LoQus23 Therapeutics has closed a £35 million ($43 million) series A financing round, led by Forbion, with support from SV Health Investors' Dementia Discovery Fund and Novartis Venture Fund. 2 October 2024
USA-based Kailera Therapeutics today announced its launch as a clinical-stage biopharmaceutical company focused on advancing a broad pipeline of next-generation therapies for the treatment of obesity and related conditions. 1 October 2024
Boston, USA-based biotech Aktis Oncology, which is targeting alpha radiopharmaceuticals to treat a broad range of solid tumors, today announced the successful closing of an oversubscribed and upsized $175 million Series B financing. 1 October 2024
Chicago, USA-based ARCH Venture Partners revealed it has closed the ARCH Venture Fund XIII, a venture capital fund with more than $3 billion to support the founding and growth of early-stage biotechnology companies. 27 September 2024
USA-based biotech funder and incubator Flagship Pioneering yesterday unveiled Mirai Bio, a company pioneering the first open end-to-end platform for the biotech industry to enable the co-creation of fully optimized genetic medicines. 27 September 2024
The UK government has released a position paper outlining its vision for Framework Programme 10 (FP10), a successor to Horizon Europe, the EU's flagship research collaboration program. 26 September 2024
Italian biotech Genespire—which is developing off-the-shelf gene therapies for pediatric patients affected by genetic diseases—has announced the closing of a 46.6 million euros ($52 million) Series B financing. 25 September 2024
Healthcare plan provider Centivo has raised $75 million in equity and debt financing to support its goal of offering affordable care to employees and their families. 25 September 2024
Rare disease firm bluebird bio has announced a company-wide restructuring aimed at cutting costs by 20% and achieving quarterly cash flow break-even by the second half of 2025. 25 September 2024
Aptadir Therapeutics, a biotech company focused on RNA inhibitor-based therapies for cancer and genetic conditions, has launched with $1.6 million in pre-seed funding. 24 September 2024
Australian biotech company Telix Pharmaceuticals is to acquire USA-based RLS Radiopharmacies, expanding its manufacturing and distribution footprint in North America. 24 September 2024
British biotech Vicebio has secured $100 million in a series B funding round to accelerate the development of its next-generation vaccines against respiratory viruses. 23 September 2024
A pre-clinical stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune disease and to bring the curative power of bone marrow transplantation to a greater number of patients suffering from otherwise incurable life-threatening diseases.
Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news